This in vitro study investigated the efficacy of genetically modified over-expressing MSCs, i.e., IL4-MSCs, PDGF-BB-MSCs, and IL4-PDGF-BB-MSCs and pMSCs for use as adjunctive cell-based therapy for CD. This evidence concerns the gene IL4 and Cowden disease.